0 results available. Select is focused ,type to refine list, press Down to open the menu,
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active In...
The following section summarizes insights on Dr Reddy’s Laboratories Ltd's P/E Ratio:
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to P/E Ratio in the valuation category include:
Indicates the multiple of earnings that stock investors are willing to pay for one share of the firm.
Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is valuation multiple that is defined as:
P/E Ratio = Market Capitalization / Net Income
or, using per-share numbers:
P/E Ratio = Stock Price / Earnings Per Share (EPS)
Applying this formula, Dr. Reddy’s Laboratories’s P/E Ratio is calculated below:
Market Capitalization [ 959.3 B ]
(/) Net Income [ 53.676 B ]
(=) P/E Ratio [ 17.9x ]
P/E Ratio indicates the multiple of earnings investors are willing to pay for one share of the company. PE Multiples are widely used in practice even though they have significant pitfalls.
Since Earnings Per Share (EPS), defined as Net Income / Shares Outstanding, uses a Net Income in the calculation, P/E multiples are not always reliable for benchmarking companies with negative earnings or debt.
One reason why P/E ratios can be unreliable is because the ratio assumes a company’s equity has value. In practice, a company’s total Firm Value may be less than the debt on its Balance Sheet, with no value allocatable to the common equity. P/E ratios also do not adjust for differences in capital structure between companies. P/E conundrum by Khan Academy does a great job of explaining these pitfalls.
The tables below summarizes the trend in Dr. Reddy’s Laboratories’s p/e ratio over the last five years:
| Date | Market Cap | Earnings | P/E Ratio |
|---|---|---|---|
| 2020-03-31 | 516.7 B | 16,200.0 | 31.9 |
| 2021-03-31 | 749.3 B | 21,256.0 | 35.3 |
| 2022-03-31 | 714.5 B | 26,317.0 | 27.1 |
| 2023-03-31 | 767.7 B | 36,350.0 | 21.1 |
| 2024-03-31 | 1,025 B | 52,206.0 | 19.6 |
Read more about net income to common excl extra items and market cap
The chart above depicts the distribution of p/e ratio for companies operating in the Healthcare sector in the Developing economic region. Over 1,190 companies were considered in this analysis, and 1,148 had meaningful values. The average p/e ratio of companies in the sector is 21.7x with a standard deviation of 59.2x.
Dr Reddy’s Laboratories Ltd's P/E Ratio of 17.9x ranks in the 47.6% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developing |
| Total Constituents | 1,196 |
| Included Constituents | 1,148 |
| Min | -280.4x |
| Max | 300.7x |
| Median | 19.1x |
| Mean | 21.7x |
| Standard Deviation | 59.2x |
You can find companies with similar p/e ratio using this stock screener.